Delving into the Latest Updates on Cariprazine hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

cariprazine, Cariprazine hydrochloride (JAN/USAN), SYMVENU

+ [11]

Target

5-HT1A receptor x 5-HT2A receptor x D2 receptor x D3 receptor

Action

agonists, antagonists, partial agonists

Mechanism

5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor partial agonists(Dopamine D2 receptor partial agonists)

Therapeutic Areas

Nervous System DiseasesOther DiseasesCardiovascular Diseases+ [1]

Active Indication

Depressive Disorder, MajorBipolar and Related DisordersBipolar Disorder+ [7]

Inactive Indication

Bipolar II disorderChronic schizophreniaGeneralized anxiety disorder+ [2]

Originator Organization

Chemical Works of Gedeon Richter Plc

Active Organization

AbbVie, Inc.Allergan, Inc.

Qilu Pharmaceutical Co., Ltd.

+ [5]

Inactive Organization

Forest Laboratories LLC

Tanabe Pharma Corp.Allergan Sales LLC

+ [1]

License Organization

Gedeon Richter (UK) Ltd.

Chemical Works of Gedeon Richter Plc

Hikma Pharmaceuticals Plc

+ [7]

Drug Highest PhaseApproved

First Approval Date

United States (17 Sep 2015),

Bipolar I disorderSchizophrenia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC21H33Cl3N4O

InChIKeyGPPJWWMREQHLQT-BHQIMSFRSA-N

CAS Registry1083076-69-0

Bipolar disorder is a common condition that can cause significant disability and risk for suicide. Second generation antipsychotic medications can be used to treat depression in bipolar disorder, yet we do not know how they work. Here, we will use a recently approved medication, cariprazine (Vraylar), to treat participants with bipolar depression. They will have brain imaging with PET scans before and during treatment to understand how the medication may be working. Particularly, we will look at the role of the D3 dopamine receptor.

Start Date06 Jan 2026

Sponsor / Collaborator

The New York State Psychiatric Institute

100 Clinical Results associated with Cariprazine hydrochloride

Login to view more data

100 Translational Medicine associated with Cariprazine hydrochloride

Login to view more data

100 Patents (Medical) associated with Cariprazine hydrochloride

Login to view more data

544

Literatures (Medical) associated with Cariprazine hydrochloride

01 May 2026·JOURNAL OF PSYCHIATRIC RESEARCH

Effect of cariprazine versus aripiprazole on cardiometabolic profile in patients with schizophrenia switched from olanzapine due to weight gain: A randomized controlled trial

Article

Author: Kumar, Pankaj ; Maharshi, Vikas ; Verma, Adarsh ; Ranjan, Rajeev

BACKGROUND:

Schizophrenia is a chronic, disabling psychotic disorder frequently treated with second-generation antipsychotics (SGAs). Although effective, SGAs such as olanzapine carry metabolic risks that elevate cardiovascular morbidity. Dopamine receptor partial agonists (DRPAs) like aripiprazole and cariprazine may mitigate these risks due to low H1 and 5-HT2C receptor affinity. While aripiprazole has shown some efficacy in reversing antipsychotic-induced weight gain, direct comparisons with cariprazine in olanzapine-switched patients are limited.

METHODS:

In this 12-week, randomized, parallel-arm trial at a tertiary care center, 98 schizophrenia patients previously on olanzapine were randomized (1:1) to cariprazine or aripiprazole. Assessments at baseline, week 6, and week 12 included weight, body mass index (BMI), waist-to-hip ratio, lipid profile, RBS, HbA1c, Positive and Negative Syndrome Scale (PANSS) and Social and Occupational Functioning Assessment Scale (SOFAS). Statistical analyses were performed using per-protocol approach with a linear mixed-effects models.

RESULTS:

Linear mixed-effects models showed a significant effect of time on body weight (F (2,176) = 11541.07, p < 0.001) and a significant treatment × time interaction (F (2,176) = 149.42, p < 0.001), while the main treatment effect was not significant (F (1, 88) = 1.34, p = 0.249). Compared with aripiprazole, cariprazine was associated with a modestly greater weight reduction over 12 weeks (mean difference = 0.82 kg). Both groups demonstrated significant within-group improvements for anthropometric, cardio-metabolic and clinical measures over 12 week; however, inter-group differences were not significant.

CONCLUSION:

Over the 12-week study period, cariprazine demonstrated greater reductions in weight than aripiprazole while maintaining comparable clinical efficacy; however with small magnitude of difference, any potential metabolic advantage should be interpreted cautiously. Larger, multicentre long-term studies are needed to confirm these findings.

CLINICAL TRIAL REGISTRATION NUMBER:

CTRI/2024/02/062615 (Registered with Clinical Trials Registry- India).

01 Apr 2026·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Tailoring cariprazine for dual disorders via secondary pharmacophore optimization

Article

Author: Vogt, Caleb D ; Saab, Elizabeth ; Ranjit, Arina ; Sanchez, Julie ; Bonifazi, Alessandro ; Lane, J Robert ; Newman, Amy Hauck ; Rais, Rana

Cariprazine is an approved drug used to treat schizophrenia, bipolar disorder, and (more recently) major depression. These serious mental illnesses are often comorbid with psychostimulant use disorders, for which no pharmacotherapeutic is currently approved. Based on preclinical data and multiple case studies, cariprazine demonstrates significant potential as a treatment for such dual disorders. Notably, this drug acts as a high-affinity (K_i = 0.22 nM) partial agonist (E_max = 45.1%) of the dopamine D₃ receptor (D₃R), a molecular target implicated in a variety of substance use disorders. Unlike other atypical antipsychotics, cariprazine is 3.6-fold more selective for D₃R than the homologous dopamine D₂ receptor (D₂R). Because patients with psychostimulant use disorders may be more susceptible to D₂R-related side effects, we hypothesized that compounds with a higher D₃R selectivity may offer a therapeutic advantage over cariprazine. By modifying part of the parent drug structure (i.e., secondary pharmacophore), analogues were developed that bind to D₃R with similar affinity (K_i = 0.248-2.97 nM) and improved selectivity over D₂R (5.0- to 39-fold). Compared to cariprazine, these derivatives behaved functionally as D₃R partial agonists and retained a similar off-target profile; however, the most promising compounds also exhibited improved metabolic stability in rat liver microsomes (t_1/2 ≥ 61.3 min). Taken together, our findings support further study of the lead candidate (8) for treating dual disorders that may have a reduced side effect profile.

04 Mar 2026·ACS Chemical Neuroscience

Intranasal Chitosan Nanoparticles for Direct Nose-to-Brain Delivery of Cariprazine: A Noninvasive Strategy for Targeted CNS Therapy

Article

Author: Jeganathan, Balamurugan ; Guntupalli, Chakravarthi ; Malothu, Narender ; Ponduri, Teja Kumar

Cariprazine is a hydrophobic antipsychotic with poor oral bioavailability and limited blood-brain barrier penetration, restricting its therapeutic potential for CNS disorders. Chitosan-based nanoparticles (CZNPs) were designed for intranasal nose to brain delivery. Key formulation variables were screened using a two level fractional factorial design (FFD) and optimized via a Box Behnken design (BBD). Nanoparticles were prepared by ionic gelation and characterized for particle size, zeta potential, and encapsulation efficiency. In vitro release, ex vivo nasal permeation (sheep mucosa), in vivo pharmacokinetics (rats), and nasal histopathology were evaluated. Optimized CZNPs exhibited a particle size of 164.8 nm, zeta potential of +45.3 mV, and 67.6 ± 0.08% encapsulation efficiency. They showed biphasic sustained release over 24 h and significantly enhanced nasal permeation versus a drug suspension. In vivo, intranasal CZNPs achieved 6.2-fold higher brain targeting efficiency, 91% direct transport percentage, and a brain to plasma AUC ratio of 0.67. Early brain C_max (106 /mL at 2 h) indicated olfactory/trigeminal transport. Relative plasma bioavailability was 91%, with no nasal epithelial or ciliary damage observed. CZNPs exhibited effective brain targeting, controlled release, and mucosal safety, highlighting their potential as a noninvasive intranasal system for CNS delivery of cariprazine in neuropsychiatric disorders.

95

News (Medical) associated with Cariprazine hydrochloride

04 Feb 2026

·firstwordpharma.com

AbbVie touts 'record' sales amid uneven quarter for immunology stars

AbbVie beat sales forecasts by about $200 million in the fourth quarter as the company's fading blockbuster Humira outperformed expectations, while successor immunology drugs Rinvoq and Skyrizi posted uneven results. "We delivered record net sales and exceeded our financial commitments," stated CEO Rob Michael during the company's earnings call.The drugmaker reported quarterly revenue of $16.6 billion, up 10% year-over-year, topping analyst estimates of $16.4 billion. Sales for the full year reached $61.2 billion, a gain of 8.6%. Despite the beat, Leerink Partners analyst David Risinger suggested Humira was "contributing the vast majority of revenue upside," which may have worried investors and could explain why AbbVie shares were down roughly 4% on Wednesday.Quarterly sales in immunology, the company's biggest segment, were up 17.7% at $8.6 billion. Skyrizi climbed 32.5% to $5 billion, surpassing expectations of $4.9 billion, while Rinvoq rose 29.5% to $2.37 billion, but fell slightly short of forecasts.On the other hand, Humira — whose sales have been steadily declining since the introduction of biosimilar competition three years ago — brought in $1.2 billion, compared to the $1 billion analysts were expecting, though the drug's quarterly sales were still nearly 26% lower year-over-year.Still, Skyrizi and Rinvoq together delivered around $25.9 billion in combined sales for 2025, which is more than $8 billion year-over-year, "well exceeding our initial guidance expectations," said Chief Commercial Officer Jeff Stewart.He touted Skyrizi's continued growth trajectory specifically, noting the drug's total prescription share in the US biologics psoriasis market is now over 45% and accelerated in the fourth quarter. "Our in-play capture rates of new and switching patients has exceeded 55% across all lines of therapy, four times higher than the next closest competitor," he added.Meanwhile, the neuroscience segment also posted strong results, with revenue rising 17.9% to $3 billion. Antipsychotic Vraylar generated $1 billion in sales, up 10.5%, while therapeutic Botox grew 13.4% to $990 million. Double-digit gains were also posted by migraine therapies Ubrelvy ($339 million, +12%) and Qulipta ($288 million, +42.6%).Parkinson's treatment Vyalev, approved in late 2024, contributed $183 million in quarterly revenue, and $482 million for all of last year, but the company believes the therapy — a 24-hour continuous subcutaneous infusion of carbidopa and levodopa prodrugs — will hit blockbuster status in 2026. "The uptake is exceptionally strong across international markets, and we expect sales to ramp in the US, where [it] recently received full coverage," Stewart said.Revenues from the oncology portfolio were $1.7 billion in the quarter, a decrease of 1.5%, with Imbruvica down 20.8% to $671 million.Looking ahead, AbbVie forecasts approximately $67 billion in revenue for 2026, representing growth of about 9.5%, with adjusted earnings between $14.37 and $14.57 per share. Skyrizi and Rinvoq are expected to make up about $21.5 billion and $10.1 billion of that total, respectively.

Financial StatementDrug ApprovalClinical ResultBiosimilar

13 Jan 2026

·www.globenewswire.com

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Jan. 06, 2026 -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 44th Annual J.P. Morgan Healthcare Conference, to take place January 12-15, 2026, in San Francisco, California. Mapi is actively seeking new partnerships for its new proprietary Depot products. Company management will be available for one-on-one meetings during the J.P. Morgan Healthcare Conference to discuss potential joint development collaborations. Interested parties should contact Mapi directly. Mapi utilizes extended-release Depot technologies protected by strong IP to develop lifecycle Management products for innovative and existing commercially successful pharmaceuticals across multiple therapeutic areas. The Company currently has one partnered product covered under a commercialization agreement, GA Depot for Relapsing Forms of Multiple Sclerosis (RMS), and other products for diabetes and schizophrenia which are funded through Phase II results. The Company’s development pipeline also includes an injectable version of cariprazine, developed using Mapi’s Depot technology, which has demonstrated a long-acting release profile, for one monthly injection. It is designed to address an unmet need for patients with schizophrenia, bipolar I and major depression disorders. Mapi recently began enrolling patients in a Phase I/II study as described in ClinicalTrials.gov ID NCT07185815. Mapi is fully integrated in the development of Depot pharmaceuticals and offers partners multiple distinct technologies. The Company has an extensive R&D team with dedicated Depot labs, an experienced clinical team, as well as a large-scale, state-of-the-art GMP approved manufacturing facility for both clinical development and commercial supply. Mapi has the capabilities to efficiently develop Depot products by integrating R&D, clinical studies, registration and manufacturing and has a successful track record of improving time to market. Ehud Marom, Chairman and Chief Executive Officer, Mapi Pharma, said, “We have a number of compelling partnering opportunities in our current pipeline, including Deutetrabenazine (AUSTEDO® XR) Depot for the treatment of Huntington's disease and tardive dyskinesia, and Anastrazole (Arimidex®) Depot as an adjuvant treatment for postmenopausal women with hormone receptor-positive early breast cancer, as well as other candidates. We are seeking to apply our technologies to co-develop Depot drugs with companies that are interested in developing long-acting injectable lifecycle management products." Mapi Pharma (Mapi) is a clinical stage pharmaceutical company, engaged in development of high barrier-to-entry and high added-value life cycle management ("LCM") products and AB Rated Depot injectable products that target large markets that include complex active pharmaceutical ingredients ("APIs") and formulations. Mapi’s lead product is GA Depot which is partnered with Viatris (NASDAQ: VTRS) in an agreement under which Viatris was granted an exclusive license to commercialize the GA Depot injection product for Relapsing Forms of Multiple Sclerosis (RMS). Following successful Phase 3 results GA Depot is currently under FDA review. The Company is also marketing its own generic versions of Fingolimod (Gilenya®) and Apremilast (Otezla®) in specific geographic markets. Mapi's portfolio also includes a leading development of Depot drugs for Schizophrenia, GLP-1 for diabetes, weight loss, with innovative intellectual property. Mapi is built on strong chemical and pharmaceutical R&D and clinical development capabilities and a deep understanding of the global market and of regulatory needs. Mapi is a global company with an API production and aseptic Depot manufacturing and a Fill & Finish for injectable Finished Dosage Forms facilities. Mapi has strong IP positions, filing numerous patent applications for APIs and formulations. For more information, please visit www.mapi-pharma.com The content above comes from the network. if any infringement, please contact us to modify.

License out/in

01 Dec 2025

·www.globenewswire.com

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Management to Participate in 8th Annual Evercore Annual Healthcare ConferenceNESS ZIONA, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 8th Annual Evercore Annual Healthcare Conference, to take place December 2-4, 2025, in Miami, Florida. Mapi is actively seeking additional partnerships for its new proprietary Depot products. Company management will be available for one-on-one meetings during the Annual Evercore Annual Healthcare Conference to discuss potential joint development collaborations. Interested parties should contact Mapi directly or their representative at Evercore to arrange a meeting. Mapi utilizes extended-release Depot technologies with strong IP to develop Lifecycle Management products for innovative and existing commercially successful pharmaceuticals across multiple therapeutic areas. The Company currently has one product which is fully under a commercialization agreement, GA Depot for Relapsing Forms of Multiple Sclerosis (RMS) and other products for diabetes and schizophrenia which are funded through Phase II results. The development pipeline also includes an injectable version of cariprazine, developed using Mapi’s Depot technology, which has demonstrated a long-acting release profile, for one monthly injection. It is designed to address an unmet need in the treatment of schizophrenia, bipolar I and major depression disorders. Mapi recently began enrolling patients in a Phase I/II study. Mapi is fully integrated in the development of Depot pharmaceuticals and offers partners multiple distinct technologies. The Company has an extensive R&D team with dedicated Depot labs, experienced clinical team, as well as a large-scale, state-of-the-art GMP approved manufacturing facility for both clinical development and commercial supply. Mapi has the capabilities to efficiently develop Depot products by integrating R&D, clinical studies, registration and manufacturing with a successful track record of improving time to market. Ehud Marom, Chairman and Chief Executive Officer, Mapi Pharma, said, “We have a number of compelling partnering opportunities in our current pipeline, including Deutetrabenazine (AUSTEDO® XR) Depot for the treatment of Huntington's disease and tardive dyskinesia, and Anastrazole (Arimidex®) Depot as an adjuvant treatment for postmenopausal women with hormone receptor-positive early breast cancer as well as other candidates. We can also apply our technologies to co-develop Depot drugs with companies that are interested in developing long-acting injectable lifecycle management versions of their molecules." About Mapi PharmaMapi Pharma (Mapi) is a clinical stage pharmaceutical company, engaged in development of high barrier-to-entry and high added-value life cycle management ("LCM") products and AB Rated Depot injectable products that target large markets that include complex active pharmaceutical ingredients ("APIs") and formulations. Mapi’s lead product is GA Depot which is partnered with Viatris (NASDAQ: VTRS) in an agreement under which Viatris was granted an exclusive license to commercialize the GA Depot injection product for Relapsing Forms of Multiple Sclerosis (RMS). Following successful Phase 3 results GA Depot is currently under FDA review. The Company is also marketing its own generic versions of Fingolimod (Gilenya®) and Apremilast (Otezla®) in specific geographic markets. Mapi's portfolio also includes a leading development of Depot drugs for Schizophrenia, GLP-1 for diabetes, weight loss, with innovative intellectual property. Mapi is built on strong chemical and pharmaceutical R&D and clinical development capabilities and a deep understanding of the global market and of regulatory needs. Mapi is a global company with an API production and aseptic Depot manufacturing and a Fill & Finish for injectable Finished Dosage Forms facilities. Mapi has strong IP positions, filing numerous patent applications for APIs and formulations. For more information, please visit www.mapi-pharma.com Contacts:Alex MogleVice President, Corporate DevelopmentMapi Pharma+972 52 6080297alex@mapi-pharma.com Brian RitchieManaging DirectorLifeSci Advisors, LLCbritchie@lifesciadvisors.com

License out/inPhase 2Phase 3

100 Deals associated with Cariprazine hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09876	Cariprazine hydrochloride	N05AX15	DB06016

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder, Major	United States	AbbVie, Inc.	16 Dec 2022
Bipolar and Related Disorders	Canada	Gedeon Richter (UK) Ltd.	27 Apr 2022
Bipolar Disorder	Canada	Allergan, Inc.	22 Apr 2022
Bipolar I disorder	United States	AbbVie, Inc.	17 Sep 2015
Schizophrenia	United States	AbbVie, Inc.	17 Sep 2015

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Septal Defects, Atrial	Phase 3	United States	AbbVie, Inc.	07 Jul 2022
Irritable Mood	Phase 3	United States	AbbVie, Inc.	07 Jul 2022
Acute schizophrenia	Phase 3	South Korea	Whan In Pharmaceutical Co., Ltd.	19 Nov 2021
Autism Spectrum Disorder	Phase 3	United States	AbbVie, Inc.	01 Feb 2021
Depressive Disorder	Phase 3	Bulgaria	Forest Laboratories LLC	17 Mar 2016
Depressive Disorder	Phase 3	Estonia	Forest Laboratories LLC	17 Mar 2016
Depressive Disorder	Phase 3	Lithuania	Forest Laboratories LLC	17 Mar 2016
Depressive Disorder	Phase 3	Poland	Forest Laboratories LLC	17 Mar 2016
Chronic schizophrenia	Phase 3	Japan	Tanabe Pharma Corp.	01 May 2012
Mania	Phase 3	United States	Forest Laboratories LLC	01 Feb 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NEWS Manual	Not Applicable	Schizophrenia	116	cariprazine (women outpatients)	mhfziwezfb(odjmnhqxme) = There was a significant change from baseline in women to week 16 in the SAND scores: negative symptoms decreased by 6.2, positive symptoms decreased with 1.0, which is a remarkable, combined 7.2 drop. fxplzbyuet (xfyhqjoqjw )	Positive	18 Oct 2023
NCT03573297 (CTgov)	Phase 3	Mania \| Depressive Disorder \| Bipolar I disorder	901	placebo (Double-Blind Placebo QD)	pfowsibjes(sgldipbxxk) = thqndgnhab himpbwvnyc (vrxjeslkic, nbkhkteger - kjqnktwfzw) View more	-	28 Sep 2023
				Cariprazine (Double-Blind Cariprazine 1.5 mg QD)	pfowsibjes(sgldipbxxk) = brmmvgroxa himpbwvnyc (vrxjeslkic, oydhefesjb - dtfhrjrkby) View more
NCT03738215 (Pubmed \| Am J Psychiatry)	Phase 3	Depressive Disorder, Major	751	Placebo	cdggzpkrib(imizctlqgc) = nmegxdboni glsdhymgao (yqzqthacuw )	Positive	15 Feb 2023
				Cariprazine 1.5 mg/day	cdggzpkrib(imizctlqgc) = avsabkbgxt glsdhymgao (yqzqthacuw )
NCT03738215 (CTgov)	Phase 3	Depressive Disorder, Major	759	Placebo (Placebo + ADT)	gmlskwtzby(ynixldqrad) = qysznoniwh fvkqjwtbee (tucyqirziu, 0.70) View more	-	25 Oct 2022
				Cariprazine (Cariprazine 1.5 mg/Day + ADT)	gmlskwtzby(ynixldqrad) = oukloilhsf fvkqjwtbee (tucyqirziu, 0.70) View more
NCT03739203 (CTgov)	Phase 3	Depressive Disorder, Major	752	Placebo (Placebo + ADT)	gpqqymhlus(hodspjljpc) = hpggcpital cgfkahjjlo (cdltjnjqve, 0.70) View more	-	21 Sep 2022
				ADT+Cariprazine (Cariprazine 1.5 mg/Day + ADT)	gpqqymhlus(hodspjljpc) = eggdfsnlge cgfkahjjlo (cdltjnjqve, 0.69) View more
NCT03593213 (CTgov)	Phase 3	Schizophrenia	587	Placebo (Placebo (Double-blind Treatment Period))	ssskibhexz(fdhufxsssj) = svyfimskmg skdfwwjjpd (vjhhtnifjd, bkqceyhxeh - jczyvshnej) View more	-	08 Mar 2022
				Cariprazine (Cariprazine 3.0 mg/Day (Double-blind Treatment Period))	ssskibhexz(fdhufxsssj) = eblkmlulzf skdfwwjjpd (vjhhtnifjd, jrsojkkwck - cytqsnxmmy) View more
NCT01626885 (CTgov)	Phase 2/3	Schizophrenia	42	MP-214	dquiyseogh = sxbyxnljgb sgipbxzkyp (zobxpqzlrs, ffuhmfzhle - spphzzumog) View more	-	13 Apr 2021
NCT01625897 (CTgov)	Phase 2/3	Chronic schizophrenia \| Schizophrenia	125	MP-214 (MP-214 1.5-9mg)	ojorzbjajs = emsraqtsjn jvuyivovrl (wecohzbyst, yyyqdqsajs - qashvsyboj) View more	-	13 Apr 2021
				risperidone (Risperidone 2-12mg)	ojorzbjajs = uhvswubewc jvuyivovrl (wecohzbyst, yfwkhkxcbz - fqnqlkjeay) View more
NCT01625000 (CTgov)	Phase 2/3	Schizophrenia	512	MP-214 3mg (MP-214 3mg)	ijlvvfavsz(roejcgmfmj) = cxpxvljmqo kxsnfbvdge (kmqrmqhdjk, 2.0) View more	-	12 Apr 2021
				MP-214 6mg (MP-214 6mg)	ijlvvfavsz(roejcgmfmj) = hvxjottfsu kxsnfbvdge (kmqrmqhdjk, 2.0) View more
NCT01626872 (CTgov)	Phase 2/3	Schizophrenia	254	MP-214 3mg (MP-214 3mg)	jqqjekjpns = iowffpgacs fuscenotbh (mmhxnjiawf, kryygyuihv - pavmjifjke) View more	-	12 Apr 2021
				MP-214 6mg (MP-214 6mg)	jqqjekjpns = owwmmoqfow fuscenotbh (mmhxnjiawf, jekebkwhmi - rikaedrqqr) View more